Search research articles
Contact Us
Filters
Showing results (811-820 of 963) with videos related to
Page
of 97
Sort By:
Seminars in Arthritis and Rheumatism
|
February 1, 2024
Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice
Sara Nysom Christiansen, Simon Horskjær Rasmussen, Marion Pons, et al.
The Journal of Rheumatology
|
December 1, 2022
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment
Lykke Midtbøll Ørnbjerg, Kathrine Rugbjerg, Stylianos Georgiadis, et al.
Arthritis Care & Research
|
January 18, 2021
Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries
Brigitte Michelsen, Stylianos Georgiadis, Daniela Di Giuseppe, et al.
Arthritis Research & Therapy
|
January 31, 2025
Differences in the response to TNF inhibitors at distinct joint locations in patients with psoriatic arthritis: results from nine European registries
Adrian Ciurea, Seraphina Kissling, Andrea Götschi, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
November 17, 2023
Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network
Pasoon Hellamand, Marleen G H van de Sande, Lykke M Ørnbjerg, et al.
Health Policy (Amsterdam, Netherlands)
|
April 17, 2025
Disparities in the organisation of national healthcare systems for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
Brigitte Michelsen, Mikkel Østergaard, Michael John Nissen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
October 28, 2016
Brief Report: The Role of Rare Protein-Coding Variants in Anti-Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis
Jing Cui, Dorothee Diogo, Eli A Stahl, et al.
Rheumatology (Oxford, England)
|
December 23, 2021
European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response
Sara Nysom Christiansen, Lykke Midtbøll Ørnbjerg, Simon Horskjær Rasmussen, et al.
Joint Bone Spine
|
April 6, 2024
Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis - relationship with the reason for withdrawal from the previous treatment
Lykke Midtbøll Ørnbjerg, Cecilie Heegaard Brahe, Louise Linde, et al.
Maturitas
|
September 14, 2016
The InterLACE study: Design, data harmonization and characteristics across 20 studies on women's health
Gita D Mishra, Hsin-Fang Chung, Nirmala Pandeya, et al.
Page
of 97
Search research articles
Search
Showing results (811-820 of 963) with videos related to
Sort By:
Page
of 97
Seminars in Arthritis and Rheumatism
|
February 1, 2024
Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice
Sara Nysom Christiansen, Simon Horskjær Rasmussen, Marion Pons, et al.
The Journal of Rheumatology
|
December 1, 2022
One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment
Lykke Midtbøll Ørnbjerg, Kathrine Rugbjerg, Stylianos Georgiadis, et al.
Arthritis Care & Research
|
January 18, 2021
Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries
Brigitte Michelsen, Stylianos Georgiadis, Daniela Di Giuseppe, et al.
Arthritis Research & Therapy
|
January 31, 2025
Differences in the response to TNF inhibitors at distinct joint locations in patients with psoriatic arthritis: results from nine European registries
Adrian Ciurea, Seraphina Kissling, Andrea Götschi, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
November 17, 2023
Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network
Pasoon Hellamand, Marleen G H van de Sande, Lykke M Ørnbjerg, et al.
Health Policy (Amsterdam, Netherlands)
|
April 17, 2025
Disparities in the organisation of national healthcare systems for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
Brigitte Michelsen, Mikkel Østergaard, Michael John Nissen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
October 28, 2016
Brief Report: The Role of Rare Protein-Coding Variants in Anti-Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis
Jing Cui, Dorothee Diogo, Eli A Stahl, et al.
Rheumatology (Oxford, England)
|
December 23, 2021
European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response
Sara Nysom Christiansen, Lykke Midtbøll Ørnbjerg, Simon Horskjær Rasmussen, et al.
Joint Bone Spine
|
April 6, 2024
Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis - relationship with the reason for withdrawal from the previous treatment
Lykke Midtbøll Ørnbjerg, Cecilie Heegaard Brahe, Louise Linde, et al.
Maturitas
|
September 14, 2016
The InterLACE study: Design, data harmonization and characteristics across 20 studies on women's health
Gita D Mishra, Hsin-Fang Chung, Nirmala Pandeya, et al.
Page
of 97